QED Therapeutics qedtx.com


Public lists: Pharma Startups (6570)

QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders. Its lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia.

QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders. Its lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory chol...Show all

Company (Alive / Active)

Phone:

Fax:

421 Kipling Street

Palo Alto, 94301
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
QED Therapeutics $65M Jan 30, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related QED Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)